Immunotherapy, targeted therapies, and combination therapies have improved survival outcomes in patients with metastatic kidney cancer.
Metastatic kidney cancer, also known as metastatic renal cell carcinoma (mRCC), is a formidable challenge in oncology. It is a type of cancer that originates in the kidneys and has spread to other parts of the body. The prognosis for metastatic kidney cancer has historically been poor, but advancements in understanding the disease’s biology and the emergence of novel treatment strategies have provided hope for improved outcomes.
Talking to The HealthSite, Dr Indranil Ghosh, Apollo Cancer Centre, Kolkata, sheds light on the prognostic factors associated with metastatic kidney cancer and highlights some of the innovative treatment approaches that have shown promise in recent years.
Prognostic Factors Linked To Metastatic Kidney Cancer
Performance Status: The patient’s overall health and ability to carry out daily activities, as measured by performance status scores, play a crucial role in predicting prognosis. Patients with a good performance status generally have a better response to treatment and improved survival outcomes.
Tumor Stage and Grade: The stage and grade of the primary kidney tumor are significant prognostic factors. Advanced tumor stage (T3 or T4) and high-grade tumors are associated with poorer outcomes in metastatic kidney cancer.
Time from diagnosis to development of metastases: If it is more than 1 year, prognosis is better.
Metastatic Burden: The extent of metastasis, including the number of metastatic sites and the involvement of vital organs, affects prognosis. Patients with limited metastatic disease tend to have a better prognosis than those with widespread metastasis.
Blood parameters: Low hemoglobin, high neutrophil and platelet counts and high calcium portend worse prognosis
READ RELATED: Eye Health: How Can Vision Problems Make It Difficult For Your Child To Focus In School?
Histology and Molecular Subtypes: The histological subtype of renal cell carcinoma (RCC) and its molecular characteristics provide valuable prognostic information. Clear cell RCC, the most common subtype, has a poorer prognosis compared to papillary or chromophobe RCC.
Novel Treatment Approaches To Fight Metastatic Kidney Cancer
Immunotherapy: Immune checkpoint inhibitors, such as programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, have revolutionized the treatment of metastatic kidney cancer. These agents help the immune system recognize and attack cancer cells. Immune checkpoint inhibitors, either as monotherapy or in combination with other agents, have shown durable responses and improved survival outcomes in patients with metastatic kidney cancer.
Targeted Therapies: Several targeted therapies have been developed to specifically inhibit pathways and molecular targets involved in the growth and progression of kidney cancer. Tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and cabozantinib, have demonstrated efficacy in metastatic kidney cancer by blocking signals that drive tumor growth and angiogenesis.
Combination Therapies: Combining immunotherapy with targeted therapies or other treatment modalities has shown promise in improving outcomes for patients with metastatic kidney cancer. For example, the combination of immune checkpoint inhibitors and TKIs has demonstrated increased response rates and prolonged survival compared to monotherapy.
Novel Approaches: Researchers are actively exploring new treatment approaches, including novel immunotherapeutic agents, personalized vaccines, and adoptive cell therapies. These innovative strategies aim to further enhance the immune system’s ability to recognize and eliminate cancer cells, providing hope for even better treatment outcomes.
Take away
Metastatic kidney cancer remains a significant challenge, but advancements in our understanding of the disease’s biology and the development of novel treatment approaches have improved prognosis and survival outcomes. Prognostic factors such as performance status, tumor stage and grade, blood parameters, metastatic burden, and molecular subtypes help guide treatment decisions and predict patient outcomes. Immunotherapy, targeted therapies, and combination approaches have shown promise in improving treatment response and prolonging survival.
Total Wellness is now just a click away.
Follow us on
window.addEventListener(‘load’, (event) => {
// $(document).ready(function(){
$(‘#commentbtn’).on(“click”,function(){
(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = “//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3”; fjs.parentNode.insertBefore(js, fjs);}(document, ‘script’, ‘facebook-jssdk’));
$(“.cmntbox”).toggle();
});
// });
});
